0000728014-15-000008.txt : 20150218 0000728014-15-000008.hdr.sgml : 20150216 20150217140526 ACCESSION NUMBER: 0000728014-15-000008 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20150217 DATE AS OF CHANGE: 20150217 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: VALEANT PHARMACEUTICALS INTERNATIONAL CENTRAL INDEX KEY: 0000930184 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330628076 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-44365 FILM NUMBER: 15620841 BUSINESS ADDRESS: STREET 1: ONE ENTERPRISE CITY: ALISO VIEJO STATE: CA ZIP: 92656 BUSINESS PHONE: 949-461-6000 MAIL ADDRESS: STREET 1: ONE ENTERPRISE CITY: ALISO VIEJO STATE: CA ZIP: 92656 FORMER COMPANY: FORMER CONFORMED NAME: ICN PHARMACEUTICALS INC DATE OF NAME CHANGE: 19941114 FORMER COMPANY: FORMER CONFORMED NAME: ICN MERGER CORP DATE OF NAME CHANGE: 19940915 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: RUANE, CUNNIFF & GOLDFARB INC CENTRAL INDEX KEY: 0000728014 IRS NUMBER: 132628641 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 9W 57TH STREET STREET 2: SUITE 5000 CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 2128325280 MAIL ADDRESS: STREET 1: 9W 57TH STREET STREET 2: SUITE 5000 CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: RUANE CUNNIFF & CO INC DATE OF NAME CHANGE: 19970618 SC 13G/A 1 vrxa.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Amendment No.: 5 Name of Issuer: Valeant Pharmaceuticals Intl Title of Class of Securities: Common CUSIP Number: 91911K102 (Date of Event Which Requires Filing of this Statement) December 31, 2014 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: /X/ Rule 13d-l(b) / / Rule 13d-l(c) / / Rule 13d-l(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP Number: 91911K102 1. Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Ruane, Cunniff & Goldfarb Inc. 13-2628641 2. Check the Appropriate Box if a Member of a Group a. / / b. / / 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power: 34,331,973 6. Shared Voting Power: NONE 7. Sole Dispositive Power: 34,331,973 8. Shared Dispositive Power: NONE 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 34,331,973 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares / / 11. Percent of Class Represented by Amount in Row (9) 10.23% 12. Type of Reporting Person IA -2- Item 1(a) Name of Issuer: Valeant Pharmaceuticals Intl (b) Address of Issuer's Principal Executive Offices: One Enterprise, Aliso Viejo, CA 92656 Item 2(a) - (c). Name, Principal Business Address, and Citizenship of Persons Filing: Ruane, Cunniff & Goldfarb Inc. 9W 57th Street, Ste 5000, New York, NY 10019 Corp. organized under the laws of the State of Delaware (d) Title of Class of Securities: Common (e) CUSIP Number: 91911K102 Item 3. This statement is filed pursuant to Rule 13d-1(b)(1). / / Broker or Dealer registered under Section 15 of the Act; /x/ Investment Adviser in accordance with Section 240.13d-1(b)(1)(ii)(E). Item 4. Ownership. (a) Amount Beneficially Owned: 34,331,973 (b) Percent of Class: 10.23% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 34,331,973 (ii) Shared power to vote or to direct the vote: NONE (iii) shares with sole power to dispose or to direct the disposition of: 34,331,973 (iv) shares with shared power to dispose or direct the disposition of: NONE Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following / /. Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A -3- Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. N/A Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of the Group. N/A Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Signature By: /s/ Todd Ruoff February 17, 2015 _______________________________ _________________ Title: Executive Vice-President Date